78508-71-1

Upstream product

• 67-56-1 methanol 
• 103987-83-3 1-nitro-2-naphthoic acid 
• 881-03-8 1-nitro-2-methylnaphthalene 
• 176853-40-0 2-<β-trans-(N,N-dimethylamino)ethenyl>-1-nitronaphthalene 

Downstream Products

• 35092-83-2 methyl 1-amino-2-naphthoate 
• 1227924-42-6 1-amino-4-bromo-2-naphthoic acid 
• 1227924-20-0 3-((1S,2S)-2-hydroxycyclohexyl)-6-((6-(methylthio)pyridin-3-yl)methyl)benzo[h]quinazolin-4(3H)-one 
• 1227924-28-8 3-((1S,2S)-2-hydroxycyclohexyl)-6-((6-methoxypyridin-3-yl)methyl)benzo[h]quinazolin-4(3H)-one 
• 1227923-29-6 3-[(1S,2S)-2-hydroxycyclohexyl]-6-[(6-methylpyridin-3-yl)methyl]benzo[h]quinazolin-4(3H)-one 
• 1227923-94-5 6-((6-chloropyridin-3-yl)methyl)-3-((1S,2S)-2-hydroxycyclohexyl)benzo[h]quinazolin-4(3H)-one 
• 1227924-49-3 3-((1S,2S)-2-hydroxycyclohexyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2yl)benzo[h]quinazolin-4(3H)-one 
• 1227924-44-8 6-bromo-3-[(1S,2S)-2-hydroxycyclohexyl]benzo[h]quinazolin-4(3H)-one 
• 1227924-43-7 1-amino-4-bromo-N-[(1S,2S)-2-hydroxycyclohexyl]-2-naphthamide 

Relevant academic research and scientific papers

CHEMISTRY OF A MEISENHEIMER-TYPE ?-ADDUCT DERIVED FROM A TROPONOID

The gem-dimethoxy ?-adduct of methoxide addition to 2-methoxy-3-nitro-4,5-benzotropone reacts with either (C2H5)3OBF4, to change the nitronate into an oxime function, or (CH3)3SiCl, to give 2-carbomethoxy-1-nitronaphthalene and the nitronic acid corresponding to the starting adduct.

MK-7622: A First-in-Class M1 Positive Allosteric Modulator Development Candidate

Identification of ligands that selectively activate the M1 muscarinic signaling pathway has been sought for decades to treat a range of neurological and cognitive disorders. Herein, we describe the optimization efforts focused on addressing key physicochemical and safety properties, ultimately leading to the clinical candidate MK-7622, a highly selective positive allosteric modulator of the M1 muscarinic receptor that has entered Phase II studies in patients with Alzheimer's disease.

M1 RECEPTOR POSITIVE ALLOSTERIC MODULATOR COMPOUNDS AND METHODS OF USE THEREOF

The present invention is directed to compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein Q, X, Y, Z, R1, R7 and n are defined herein. The compounds of Formula (I) are M1 receptor positive allosteric modul

DIHYDROBENZOQUINAZOLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS

The present invention is directed to dihydrobenzoquinazilinone compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease

PYRANYL ARYL METHYL BENZOQUINAZOLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS

The present invention is directed to pyranyl aryl methyl benzoquinazolinone compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as ALzheimer?s disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor

AMINOBENZOQUINAZOLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS

The present invention is directed to aminobenzoquinazolinone compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimers disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor

ARYL METHYL BENZOQUINAZOLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS

The present invention is directed to benzoquinazilinone compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.